Table 3 Summary of the literature for the differentially expressed EV-miRNAs between NW and OW/Ob breast cancer patients

hsa-let-7a-5p

Decreased expression of circulating EV-derived miRNA-let-7a in inflammatory breast cancer (IBC) patients compared to non-IBC and health controls

[52]

Decreased expression of circulating miRNA-let-a in breast cancer patients compared to health controls

[59]

Decreased expression of circulating miRNA-let-a in post-operative breast cancer patients compared to control subjects

[60]

Decreased expression of circulating miRNA-let-a in breast cancer compared to the control group and the benign breast lesions group. Negative correlation of circulating miRNA-let-a with development of metastases

[61]

Decreased expression of circulating miRNA-let-a in non-metastatic breast cancer patients following the common treatments, such as surgery, chemotherapy, and radiotherapy compared to the control ones. Increased expression of circulating miRNA-let-a in non-metastatic breast cancer patients after surgery, chemotherapy, and radiotherapy treatments than the pre-treatment

[62]

Decreased expression of circulating miRNA-let-a in diabetic patients compared to healthy individuals

[63]

Down-regulation of peripheral blood mononuclear cells (PBMC)-derived miRNA let-7a in children with metabolic-associated fatty liver disease (MAFLD) and insulin resistance

[64]

Decreased expression of circulating miRNA-let-a in obese subjects with metabolic syndrome (MetS) compared to non-Met patients

[65]

hsa-miR-122-5p

Up-regulation of plasma‐derived exosomes miRNA‐122 in breast cancer patients compared to normal controls

[66]

Positive correlation of circulating miR-122 with clinical outcomes including neoadjuvant chemotherapy, response and relapse with metastatic disease

[67]

Increased expression of circulating miRNA-122 in locally advanced primary breast cancer patients treated with neoadjuvant chemotherapy

[68]

Positive correlation of increased expression of circulating miRNA-122 with obesity, insulin resistance, metabolic syndrome, type 2 diabetes, adverse lipid profile and non-alcoholic fatty liver disease

[69, 82,83,84]

Negative correlation of circulating miRNA-122 levels with brown adipose tissue activity and serum HDL-cholesterol; positive correlation with BMI, body fat mass, total cholesterol and triglyceride serum levels

[70]

Increased expression of circulating miRNA-122 in subjects with the metabolic syndrome (MetS) compared to non-Met ones; decreased expression of circulating miRNA-122 in response to weight loss

[71]

Increased expression of circulating miRNA-122 in children with obesity compared to health controls

[72, 85]

Positive correlation of circulating miRNA-122 levels with clinical and biochemical markers of obesity and insulin resistance in adolescents

[73]

Increased expression of circulating miRNA-122 in children with nonalcoholic fatty liver disease compared to healthy controls

[74]

Decreased expression of circulating miRNA-122 in women with pregestational obesity and gestational obesity compared to normal pregnancies (control)

[75]

hsa-miR-30d

Positive correlation of circulating miRNA-30d levels with clinical and biochemical markers of obesity and insulin resistance in adolescents

[73]

hsa-miR-126-3p

Decreased expression of circulating miRNA-126 in type 2 diabetes

[76, 86]

Increased expression of circulating miRNA-126 in subjects with obesity

[77]

hsa-miR27b-3p

Decreased expression of circulating EV-derived miRNA- 27b in triple negative breast cancer patients compared to Her2-positive

[78]

Positive correlation of circulating miRNA-27b levels with body mass index in children

[72]

Increased expression of circulating miRNA-27b in obese children compared to healthy controls

[79]

hsa-miR-4772-3p

Positive correlation of peripheral blood mononuclear cells (PBMC)-derived miRNA-4772 levels with the magnitude of weight loss in subjects with obesity

[80]

hsa-miR10a-5p

Increased expression of circulating miRNA-10a in women with clinically stable metastatic breast cancer responders to post lifestyle intervention (diet and physical activity) compared with their baseline and non-responders

[81]